Table 4. CYP3A4, CYP3A5, and ABCB1 SNP associations with toxicity outcomes reported in previous studies.

Study	Patient cohort (n)	Toxicity outcome	SNP	OR (95% CI)	p value	Multiple testing
Diekstra [23]	mRCC, sunitinib (333)	Hypertension	CYP3A4 rs4646437	2.4 (1.1–5.2)	0.021	No
Garcia-Donas [19]	mRCC, sunitinib (84)	Toxicity-related DR	CYP3A5 rs776746	3.75 (1.67–8.41)	0.022	Yes
Diekstra [11]	mRCC, sunitinib (333)	Hypertension	CYP3A5 rs776746	4.70 (1.47–15.0)	0.009	Yes
		Toxicity-related DR		2.04 (1.04–4.00)	0.039	Yes
Van Erp [12]	mRCC, sunitinib (219)	Hand-foot syndrome	ABCB1 rs1045642/ rs1128503/ rs2032582 haplotype	0.39 (0.16–0.94)	0.035	Yes
Beuselinck [30]	mRCC, sunitinib (96)	Median time to DR	ABCB1 rs1128503	2.278 (1.07–4.82)	0.031	No
			ABCB1 rs2032582	2.106 (1.01–4.37)	0.046	No
Garcia-Donas [19]	cc-mRCC, sunitinib (101)	Hypertension	ABCB1 rs1128503 ABCB1 rs2032582	0.41 (0.20–0.81) 0·42 (0·21–0·84)	0.011 0.014	No
Diekstra [11]	mRCC, sunitinib (333)	Mucosal inflammation	ABCB1 rs1128503/ rs2032582	0.19 (0.04–0.83)	0.028	Yes
		Toxicity grade >2	ABCB1 rs1045642		0.04	No

SNP = single-nucleotide polymorphism; OR = odds ratio; CI = confidence interval; mRCC = metastatic renal cell carcinoma; cc = clear cell; DR = dose reduction